Literature DB >> 8902457

Determinants of survival in pulmonary Langerhans' cell granulomatosis (histiocytosis X). Groupe d'Etude en Pathologie Interstitielle de la Société de Pathologie Thoracique du Nord.

A Delobbe1, J Durieu, A Duhamel, B Wallaert.   

Abstract

The course of pulmonary Langerhans' cell granulomatosis (pulmonary LCG) is variable, difficult to predict and ranges from spontaneous remission to progressive respiratory insufficiency and death. To identify the determinants of survival, we performed a survival analysis on 45 patients with pulmonary LCG. The patients were aged 28 +/- 10 yrs (mean +/- SD) (range 12-62 yrs), 32 males and 13 females, almost exclusively current smokers (96%), and 78% presented symptoms at the time of diagnosis. Diagnosis was made by lung biopsy in 25 patients (56%) and by bronchoalveolar lavage (BAL) analysis in 20 patients (44%). The patients were followed for a median period of 6 yrs (range 1-29 yrs) after the diagnosis. During the period of observation, 33 (73%) patients survived (median follow-up period = 5.8 yrs; range, 1-29 yrs) and 12 (27%) died or underwent lung transplantation (median follow-up period = 8.4 yrs; range 1.4 - 16.1 yrs). The median survival was approximately 13 years. A univariate analysis demonstrated that diminished survival was significantly associated with: an older age at diagnosis (p = 0.0001); a lower forced expiratory volume in one second/forced vital capacity (FEV1/FVC) ratio at diagnosis (p = 0.005); a higher residual volume/total lung volume (RV/TLC) ratio at diagnosis (p = 0.02); and steroid therapy during follow-up (p = 0.03). Additional predictive information on mortality was: age > 26 yrs (sensitivity 83%, specificity 64%); FEV1/FVC ratio < 0.66 (sensitivity 75%, specificity 86%); and a RV/TLC ratio > 0.33 (sensitivity 75%, specificity 63%). In multivariate Cox analysis, the combination of factors which gave the best prognostic value was FEV1/FVC ratio and age (p < 0.01). The present findings suggest that adverse prognosis factors at diagnosis in pulmonary Langerhans' cell granulomatosis include older age, lower FEV1/FVC ratio and higher RV/TLC ratio, with additional predictive information on mortality if aged > 26 yrs, FEV1/FVC ratio < 0.66, and RV/TLC ratio > 0.33.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8902457     DOI: 10.1183/09031936.96.09102002

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  16 in total

Review 1.  Adult pulmonary Langerhans' cell histiocytosis.

Authors:  A Tazi; P Soler; A J Hance
Journal:  Thorax       Date:  2000-05       Impact factor: 9.139

Review 2.  The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction.

Authors: 
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

Review 3.  Rare lung diseases III: pulmonary Langerhans' cell histiocytosis.

Authors:  Stephen C Juvet; David Hwang; Gregory P Downey
Journal:  Can Respir J       Date:  2010 May-Jun       Impact factor: 2.409

Review 4.  Unusual causes of pneumothorax.

Authors:  Daniel R Ouellette; Scott Parrish; Robert F Browning; J Francis Turner; Konstantinos Zarogoulidis; Ioanna Kougioumtzi; Georgios Dryllis; Ioannis Kioumis; Georgia Pitsiou; Nikolaos Machairiotis; Nikolaos Katsikogiannis; Theodora Tsiouda; Athanasios Madesis; Theodoros Karaiskos; Paul Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 5.  Histiocytic disorders.

Authors:  Kenneth L McClain; Camille Bigenwald; Matthew Collin; Julien Haroche; Rebecca A Marsh; Miriam Merad; Jennifer Picarsic; Karina B Ribeiro; Carl E Allen
Journal:  Nat Rev Dis Primers       Date:  2021-10-07       Impact factor: 65.038

Review 6.  Cigarette smoking and diffuse lung disease.

Authors:  Rajesh R Patel; Jay H Ryu; Robert Vassallo
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 7.  Challenges in pulmonary fibrosis. 3: Cystic lung disease.

Authors:  Gregory P Cosgrove; Stephen K Frankel; Kevin K Brown
Journal:  Thorax       Date:  2007-09       Impact factor: 9.139

Review 8.  Langerhans cell histiocytosis.

Authors:  Joan Manel Gasent Blesa; Vicente Alberola Candel; Carlos Solano Vercet; Juan Laforga Canales; Christof Semler; Maria Rosa Pérez Antolí; Carlos Rodríguez-Galindo
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.340

9.  Pulmonary hypertension in pulmonary langerhans cell granulomatosis.

Authors:  Matthias Held; Philipp Schnabel; Arne Warth; Berthold Jany
Journal:  Case Rep Med       Date:  2012-03-13

Review 10.  Pulmonary langerhans cell histiocytosis.

Authors:  Harpreet S Suri; Eunhee S Yi; Gregorz S Nowakowski; Robert Vassallo
Journal:  Orphanet J Rare Dis       Date:  2012-03-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.